The Latest Breaking News from ALGN

Align Technology has significantly underperformed the Dow over the past year, yet analysts remain optimistic about the stock’s prospects.

Despite Align Technology’s underperformance relative to the broader market over the past year, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.

Align Technology is scheduled to report its fourth-quarter results next month, and analysts expect a single-digit earnings growth.

Align Technology has underperformed the Nasdaq over the past year, but analysts are moderately optimistic about the stock’s prospects.

Despite Align Technology’s underperformance relative to the broader market over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Align Technology will release its third-quarter earnings this month, and analysts anticipate a double-digit bottom-line growth.

Despite Align Technology’s underperformance compared to the S&P 500 Index over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Despite Align Technology’s underperformance relative to the broader market over the past year, Wall Street analysts remain moderately bullish about the stock’s prospects.

With an aging population, increasing drug demand, and the development of advanced technologies, the healthcare industry is booming. Thus, it could be wise to invest in fundamentally sound healthcare stocks, Veeva Systems (VEEV), Align Technology (ALGN), and Medpace Holdings (MEDP), which have high-profit margins. Read on.

Align Technology is all set to release its second-quarter earnings this month, and analysts project a high-single-digit bottom-line increase.

As American teenagers age into adulthood, they'll bring many of their favorite brands with them.